(Registrieren)

EANS-Voting Rights: Epigenomics AG / Release of a voting rights announcement according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim of a Europe-wide distribution

Geschrieben am 22-04-2010


--------------------------------------------------------------------------------
Notification of voting rights transmitted by euro adhoc. The issuer is
responsible for the content of this announcement.
--------------------------------------------------------------------------------



Person/company obliged to make the notification:



-----------------------------------



Name: see notification
Place: New York, NY
State: USA



Company data:
-----------------------



Name: Epigenomics AG
Address: Kleine Präsidentenstraße 1, 10178 Berlin
Place: Berlin
State: Deutschland



Voting Rights: Release of a Voting Rights Notification Pursuant to § 26, para.
1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide
Distribution



Issuer:



Epigenomics AG
Kleine Präsidentenstr. 1
10178 Berlin
Germany



Voting Rights Notification:



On 21 April 2010, Julian Baker, USA, notified Epigenomics AG of voting rights
in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22
para. 1 sent. 1 no. 1 WpHG and sec. 22 para. 2 WpHG as follows:



On 19 April 2010, the share of Julian Baker in the voting rights of Epigenomics
AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 5.12 per cent of the voting rights (i.e., 2,257,212 voting
rights of the 44,092,085 shares outstanding at that date) in Epigenomics AG.



All 5.12 per cent of the voting rights (2,257,212 voting rights) are attributed
to Julian Baker pursuant to Sec. 22 para. 1 sent. 1 no. 1 WpHG through the
following entities controlled by Julian Baker:



• Baker Brothers Life Sciences Capital (GP), LLC
• Baker Brothers Life Sciences Capital, L.P.
• Baker Brothers Life Sciences, L.P.

All 5.12 per cent of the voting rights (2,257,212 voting rights) of Baker



Brothers Life Sciences, L.P. are additionally attributed to Julian Baker
pursuant to sec. 22 para. 2 WpHG.



Furthermore, on 21 April 2010, Felix Baker, USA, notified Epigenomics AG of
voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection
with sec. 22 para. 1 sent. 1 no.1 WpHG and sec. 22 para. 2 WpHG as follows:



On 19 April 2010, the share of Felix Baker in the voting rights of Epigenomics
AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights)
in Epigenomics AG.



All 5.12 per cent of the voting rights (2,257,212 voting rights) are
attributed to Felix Baker pursuant to sec. 22 para. 1 sent. 1 no.1 WpHG through
the following entities controlled by Felix Baker:



• Baker Brothers Life Sciences Capital (GP), LLC
• Baker Brothers Life Sciences Capital, L.P.
• Baker Brothers Life Sciences, L.P.

All 5.12 per cent of the voting rights (2,257,212 voting rights) of Baker



Brothers Life Sciences, L.P. are additionally attributed to Felix Baker
pursuant to sec. 22 para. 2 WpHG.



Furthermore, on 21 April 2010, Baker Brothers Life Sciences Capital (GP), LLC,
New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.
1 WpHG and sec. 22 para. 2 WpHG as follows:



On 19 April 2010, the share of Baker Brothers Life Sciences Capital (GP), LLC
in the voting rights of Epigenomics AG exceeded the 5 per cent threshold of
sec. 21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the
voting rights (2,257,212) in Epigenomics AG.



5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to
Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 1
sent. 1 no. 1 WpHG through the following entities controlled by Baker Brothers
Life Sciences Capital (GP), LLC:



• Baker Brothers Life Sciences Capital, L.P.
• Baker Brothers Life Sciences, L.P.

0.12 per cent of the voting rights (52,573 voting rights) are attributed to



Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 2
WpHG.



Furthermore, on 21 April 2010, Baker Brothers Life Sciences Capital, L.P., New
York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.
1 WpHG and sec. 22 para. 2 WpHG as follows:



On 19 April 2010, the share of Baker Brothers Life Sciences Capital, L.P. in
the voting rights of Epigenomics AG exceeded the 5 per cent threshold of sec.
21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the voting
rights (2,257,212) in Epigenomics AG.



5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to
Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 1 sent. 1
no. 1 WpHG through the following entity controlled by Baker Brothers Life
Sciences Capital, L.P.:



• Baker Brothers Life Sciences, L.P.



0.12 per cent of the voting rights (52,573 voting rights) are attributed to
Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 2 WpHG.



Furthermore, on 21 April 2010, Baker Brothers Life Sciences, L.P., New York,
NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to
sec. 21 para. 1 WpHG in connection with sec. 22 para. 2 WpHG as follows:



On 19 April 2010, the share of Baker Brothers Life Sciences, L.P. in the voting
rights of Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1
WpHG and amounted, as at this date, to 5.12 per cent of the voting rights
(2,257,212 voting rights) in Epigenomics AG.



0.12 per cent of the voting rights (52,573 voting rights) are attributed to
Baker Brothers Life Sciences, L.P. pursuant to sec. 22 para. 2 WpHG.



Furthermore, on 21 April 2010, 14159 Capital (GP), LLC, New York, NY, USA
notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21
para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22
para.2 WpHG as follows:



On 19 April 2010, the share of 14159 Capital (GP), LLC in the voting rights of
Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212
voting rights) in Epigenomics AG.



0.12 per cent of the voting rights (52,573 voting rights) are attributed to
14159 Capital (GP), LLC pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.



5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to
14159 Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG through Baker Brothers
Life Sciences, L.P.



Furthermore, on 21 April 2010, 14159 Capital, L.P., New York, NY, USA notified
Epigenomics AG of voting rights held in Epigenomics AG pursuant to sen. 21
para. 1 WpHG in connection with sen. 22 para. 1 sent. 1 no. 1 WpHG and sen. 22
para.2 WpHG as follows:



On 19 April 2010, the share of 14159 Capital, L.P. in the voting rights of
Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212
voting rights) in Epigenomics AG.



0.12 per cent of the voting rights (52,573 voting rights) are attributed to
14159 Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.



5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to
14159 Capital, L.P. pursuant to sec. 22 para. 2 WpHG through Baker Brothers
Life Sciences, L.P.



Furthermore, on 21 April 2010, 14159, L.P., New York, NY, USA, notified
Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1
WpHG in connection with sec. 22 para.2 WpHG as follows:



On 19 April 2010, the share of 14159, L.P. in the voting rights of Epigenomics
AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights)
in Epigenomics AG.



5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to
14159, L.P. pursuant to Sec. 22 para. 2 WpHG through Baker Brothers Life
Sciences, L.P.



Date of release: 22 April 2010



Epigenomics AG
The Executive Board



Contact:



Epigenomics AG
Dr. Achim Plum
Senior Vice President Corporate Development
Tel.: +49 (0)30 24345 368
Fax: +49 (0)30 24345 555
Email: achim.plum@epigenomics.com



end of announcement euro adhoc
--------------------------------------------------------------------------------


ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:


Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

264064

weitere Artikel:
  • EANS-Stimmrechte: Epigenomics AG / Korrektur: Veröffentlichung gemäß § 26 Abs. 1 Satz 1 WpHG mit dem Ziel der europaweiten Verbreitung -------------------------------------------------------------------------------- Stimmrechtsmitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Angaben zum Mitteilungspflichtigen: ----------------------------------- Name: ICF Kursmakler AG Sitz: Frankfurt Staat: Deutschland Angaben zum Emittenten: ----------------------- Name: Epigenomics AG Adresse: Kleine mehr...

  • EANS-Tip Announcement: KSB AG / Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG (the German Securities Act) with the objective of Europe-wide distribution -------------------------------------------------------------------------------- Tip announcement for financial statements transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- The company KSB AG is declaring its financial reporting publication plan below: Report Type: Group-Interim Announcement Within The First Half Of The Year German: Publication Date : 04.05.2010 Publication Location: http://www.ksb.com/finanzberichte mehr...

  • EANS-Hinweisbekanntmachung: KSB AG / Bekanntmachung gemäß § 37v, 37w, 37x ff. WpHG mit dem Ziel der europaweiten Verbreitung -------------------------------------------------------------------------------- Hinweisbekanntmachung für Finanzberichte übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Hiermit gibt die KSB AG bekannt, dass folgende Finanzberichte veröffentlicht werden: Bericht: Konzern-Zwischenmitteilung innerhalb des 1. Halbjahres Deutsch: Veröffentlichungsdatum: 04.05.2010 Veröffentlichungsort mehr...

  • EANS-Stimmrechte: MVV Energie AG / Veröffentlichung gemäß § 26 Abs. 1 Satz 1 WpHG mit dem Ziel der europaweiten Verbreitung -------------------------------------------------------------------------------- Stimmrechtsmitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Angaben zum Mitteilungspflichtigen: ----------------------------------- Name: siehe Meldungstext unten Sitz: siehe Meldungstext unten Staat: siehe Meldungstext unten Angaben zum Emittenten: ----------------------- Name: mehr...

  • EANS-Voting Rights: MVV Energie AG / Release of a voting rights announcement according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim of a Europe-wide distribution -------------------------------------------------------------------------------- Notification of voting rights transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- Person/company obliged to make the notification: ----------------------------------- Name: see announcement below Place: see announcement below State: see announcement below Company data: ----------------------- Name: MVV Energie AG Address: mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht